DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo


company name or ticker

Is Vivus Headed Towards An Unfortunate Ending?

The Newest FDA-Approved Obesity Drug Is Also the Oldest

Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.

3 Stocks Poised for Eye-Popping Gains in 2015

Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.

First Week Of March 2015 Options Trading For Arena Pharmaceuticals

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog

3 Biotech Stocks I Don't Want for Christmas

I’d prefer coal in my stocking to these three troubled biotech stocks.

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

Contrave Prescriptions Still Rising In A Down Week

Orexigen - Contrave Script Numbers Remain Impressive

See More Articles...